Similar companies
Related EMIS Industry Reports
Since the establishment, the company has been specializing in the research, development, and production of synthetic peptide medications. The advantage of the company relies on the technologies it holds on the large-scale, low-cost, and GMP-certified production of polypeptide raw materials and formulas. The key product of the company, Jitai (thymosin α1 for injection, a protein that is used in the treatment of Hepatitis B and C), is the 2nd domestic brand in China of the similar products. In addition, the company has also developed and marketed thymopetin and somatostatin. The company is currently developing and pending for approval on other products such as eptifibatide, exenatide, bivalirudin, and teriparatide. According to the release document, the company also holds 7 national drug certifications and 37 drug registration approvals in China.
Headquarters
No. 16, Xingguo Road, Xiuying District, Haikou City, Hainan Province
Haikou; Hainan;
Postal Code: 570314
Contact Details: Purchase the Hainan Shuangcheng Pharmaceuticals Co., Ltd. report to view the information.
Website: http://www.shuangchengmed.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
To view more information, Request a demonstration of the EMIS service